May 25, 2023

Five-year overall survival improved by 30% for children with acute lymphoblastic leukemia (ALL) who were treated at the Hospital General-Tijuana in Mexico, after implementation of a cross-border cancer treatment training and access program facilitated in partnership with Rady Children’s Hospital-San Diego and St. Jude Children’s Research Hospital. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and is in press with JCO Global Oncology for publication on Saturday, June 3.

May 25, 2023

Minimally invasive distal pancreatectomy with splenectomy is a safe and effective alternative to traditional open surgery for patients with resectable pancreatic cancer, according to results from DIPLOMA, an international randomized trial. This surgical approach, which removes tumors located on the body or the tail of the pancreas and the spleen, uses smaller incisions and offers a lower risk of serious complications compared to open surgery. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.  

May 25, 2023

Adding the immunotherapy drug pembrolizumab (Keytruda®) to chemotherapy, with or without bevacizumab (Avastin®), improved overall survival (OS) and progression-free survival (PFS) in people with persistent, recurrent, or metastatic cervical cancer, regardless of whether the cancer expressed PD-L1. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.  

May 25, 2023

Patients with breast cancer in the overweight or obese body mass index (BMI) ranges can achieve meaningful weight loss through a telephone-based intervention. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

May 19, 2023

ALEXANDRIA, Va. – Jeremy Lyle Warner, MD, MS, FAMIA, FASCO, has been appointed as the next Editor-in-Chief of JCO Clinical Cancer Informatics (JCO CCI), an American Society of Clinical Oncology (ASCO) journal. JCO CCI is an online-only interdisciplinary journal with a primary focus on how information systems help us learn from and improve cancer care, how they interact with each other, and how they serve to advance the field of cancer medicine. 

May 17, 2023

The American Society of Clinical Oncology (ASCO) will host ASCO Breakthrough, a global oncology meeting in Asia, to shine a light on novel and cutting-edge advances that are transforming cancer care.

May 15, 2023

Today President Biden announced the nomination of current National Cancer Institute Director (NCI), Dr. Monica Bertagnolli, to become Director of the National Institutes of Health (NIH).

May 9, 2023

Oncology professionals from around the world will convene in Chicago to discuss the latest clinical cancer research impacting patient care at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Optimizing care for patients, improving access to cancer care, and developing novel treatments are among the topics that will be highlighted in the meeting’s official Press Program.  

May 1, 2023

ALEXANDRIA, Va. – More than 150 members of the Association of Clinical Oncology (ASCO), the leading professional organization for oncology professionals, will meet with Members of Congress on Tuesday urging them to make cancer care a top priority.

“Lawmakers have a profound effect on cancer patients and their doctors. From funding the research that leads to new groundbreaking treatments, to ensuring those treatments are covered by insurance and accessible and affordable to patients; lawmakers play a pivotal role,” said ASCO Board Chair Lori J. Pierce, MD, FASTRO, FASCO.

April 19, 2023

Today members of the U.S. House of Representatives unveiled a proposed legislative deal to reduce federal spending in exchange for raising the nation’s debt ceiling. The proposal includes significant funding cuts to federal agencies, which would include resources for the National Institutes of Health (NIH) and National Cancer Institute (NCI). It also proposes adding work requirements for Medicaid enrollment.

A statement from Dr. Julie Gralow, Chief Medical Officer and Executive Vice President, Association of Clinical Oncology follows:

April 19, 2023

Adding toripalimab to perioperative chemotherapy led to an improvement in event-free survival for patients with stage III resectable non-small cell lung cancer (NSCLC), according to research that will be presented during the April 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.  

April 19, 2023

In patients with KRASG12C mutated cancers, adagrasib, an oral drug that targets KRASG12C, may be an effective treatment, according to research that will be presented during the April 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.  

April 3, 2023

ALEXANDRIA, Va.—Today the National Cancer Institute (NCI) released an ambitious National Cancer Plan designed to accelerate scientific progress against the disease, maximize the potential of discovery and achieve the goal of the Cancer Moonshot initiative to “end cancer as we know it.”

March 30, 2023

ALEXANDRIA, Va. – “Today’s ruling is a significant step backward in the effort to reduce cancer incidence and death. By reversing the now more than decade-long requirement that insurance plans cover proven cancer screenings—including those for breast, colon, and lung—health plans could reinstate cost-sharing and patients could once again be forced to weigh the potentially lifesaving benefit of a doctor-recommended cancer screening against the out-of-pocket costs it may generate.

March 23, 2023

Dr. Brian Persing, a medical oncologist and hematologist in Mobile, Alabama and member of the Association of Clinical Oncology (ASCO), the world’s leading professional organization representing nearly 45,000 oncology professionals, will testify before the House Appropriations Subcommittee on Labor Health and Human Services and Education today in support of increased federal funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control. He will also advocate for robust funding of the Advanced Research Projects Agency for Health (ARPA-H). 

Pages